Escitalopram and Depression in Elderly Alzheimer's Patients

This study has been terminated.
(Dr. Rabheru left VCH last year and the study was cancelled according to his research coordinator.)
Sponsor:
Information provided by:
University of British Columbia
ClinicalTrials.gov Identifier:
NCT00488670
First received: June 18, 2007
Last updated: June 2, 2011
Last verified: June 2011

June 18, 2007
June 2, 2011
December 2010
June 2011   (final data collection date for primary outcome measure)
Change in Cornell Scale for Depression in Dementia (CSDD) from baseline. [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.
Complete list of historical versions of study NCT00488670 on ClinicalTrials.gov Archive Site
Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer’s Disease Cooperative Study
Not Provided
Not Provided
 
Escitalopram and Depression in Elderly Alzheimer's Patients
An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Depressive Disorder
Drug: Escitalopram
See Detailed Description.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
50
June 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • > 50 years
  • Male & female
  • Alzheimer's disease
  • Depressive episode
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00488670
H07-00050
No
Dr. Kiran Rabheru, University of British Columbia
University of British Columbia
Not Provided
Principal Investigator: Kiran Rabheru, MD University of British Columbia
University of British Columbia
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP